IUC26662-87

Abstract Code: IUC26662-87   Ultra-low PSA as a real-world indicator of androgen receptor pathway inhibitors (ARPI) treatment response in metastatic prostate cancer M. Ghigeanu 1, I. Bogatu 2, M.A. Barbu 3 (1) Bucharest Institute of Oncology – Romania, (2)...

IUC26661-86

Abstract Code: IUC26661-86   Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide – A single centre study K. Marchon 1, S. Brown 1, K. Swaminathan 1, S. Adeyemi 1, G....

IUC26659-93

Abstract Code: IUC26659-93   Transdermal Estradiol as an Alternative to LHRH Agonists in Prostate Cancer Management D. Khanna 1, S. Debra 1, D. Sethi 1, M. Abdel-Missih 1 (1) The University of Buckingham Medical School, Crewe – United Kingdom  ...

IUC26655-89

Abstract Code: IUC26655-89   Pretreatment Hemoglobin-Albumin-Lymphocyte-Platelet Score, Dosimetry, and Acute Toxicity After Definitive Prostate Radiotherapy: Interim Real-World Evidence B. Depboylu 1, T. Bahceci 2, H. Onder 3, Y. Yalcin 4 (1) Aydin Adnan Menderes...

IUC26651-85

Abstract Code: IUC26651-85   AI-assisted Biparametric vs Multiparametric MRI for Clinically Significant Prostate Cancer A. Tiwari 1, K. Bhagat 2, U. Khan 3, J.K. Tan 4, D. Sethi 5, A. Maniam 6, G. Banna 7, A. Khan 8, A. Ghose 1 (1) Cancer AI Validation Lab,...
error: Content is protected !!